PEAK6 Investments’s Krystal Biotech KRYS Stock Holding History

PEAK6 Investments’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-797	Closed	-$111K	–	4391
2023 Q4	$98.9K	Buy	+797	New	+$88.4K	﹤0.01%	3548

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PEAK6 Investments's KRYS Position: Q1 2024 in Review

PEAK6 Investments sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 797 shares — an estimated $111K sold.

PEAK6 Investments first reported a position in KRYS in Q4 2023 and held it in 1 quarter. The position peaked at $98.9K in Q4 2023. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

PEAK6 Investments reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
PEAK6 Investments sold 797 Krystal Biotech shares in Q1 2024, an estimated $111K.
PEAK6 Investments first reported a position in Krystal Biotech in Q4 2023 and held it in 1 quarter.
PEAK6 Investments's Krystal Biotech position peaked at $98.9K in Q4 2023.
234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on PEAK6 Investments's 13F filing for Q1 2024, filed 14 May 2024.